Home > Blog

Blog | Veristat, The Science-First CRO

Gain the latest insights and trends in clinical trials, patient recruitment, data analysis, adaptive design, regulatory submissions and approvals.

Sign Up Today

1 min read

Accelerate Neurology/Psychiatry Trial Success with Expert Guidance

Learn how our neuroscience team partner with sponsors across multiple therapeutic areas to accelerate trial success in complex neurological and psychiatric conditions. Our collaborative efforts have supported successful marketing applications,...

READ MORE

4 min read

Single-Arm Studies: A Strategic Path to Oncology Drug Approval

In oncology drug development, randomized controlled trials (RCTs) are the gold standard for generating data to secure regulatory approval. The recent FDA Project Frontrunner (to read more about Veristat’s thoughts on Project Frontrunner, click here)...

READ MORE

1 min read

IND Success Strategy: Building a High-Quality IND from Scratch with Strategic Gap Analysis

Learn how our regulatory affairs team was able to work with a sponsor to build a complete, FDA-compliant IND from scratch. Our collaborative efforts led to successful IND submission and initiation of clinical trials with confidence, preventing potential...

READ MORE

3 min read

Trends in Oncology Regulation: FDA Draft Guidance on OS and Radiopharmaceuticals

Over the past two decades, the FDA has steadily increased the number of guidance documents it publishes each year. The agency issued about 101 guidance documents annually from 2005–2010, rising to 173 per year between 2011–2019, and more than 190 in FY...

READ MORE

4 min read

Monthly FDA Guidance and Regulatory News Review - July 2025

Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA) that are pertinent to the governance of clinical trials and drug, biologic, or medical device development...

READ MORE

1 min read

NDA Success Strategy: Using Non-US Clinical Data in an NDA Submission

When our sponsor acquired an investigational asset from an international company, they faced a critical regulatory challenge: Could clinical data from foreign trials not conducted under a U.S. IND be included in their New Drug Application? The foreign...

READ MORE

2 min read

From Clinical Strategy to Patient Impact: 5 Lessons from Cindy Henderson

In a recent Trailblazers interview, Cindy Henderson, Chief Strategy Officer at Veristat, shared her inspiring career journey from the mailroom to the executive team. Her story is packed with insights for anyone working in clinical research—from clinical...

READ MORE

3 min read

On Track and In Sync: How Veristat Continues to Support Efficient FDA Interactions

In today’s regulatory climate, reports of staffing shortages and slowed review timelines at the FDA have sparked anxiety across the biopharma industry — especially for sponsors preparing for key submissions like INDs or NDAs. At Veristat, however, our...

READ MORE

1 min read

FDA’s Project FrontRunner: A Path Forward for Cancer Drug Development

The FDA’s Oncology Center of Excellence (OCE) is shifting the paradigm in cancer treatment development with Project FrontRunner— an initiative designed to encourage drug sponsors to develop, test, and seek approval of new cancer drugs for advanced or...

READ MORE

2 min read

Cross-Functional Collaboration: A Cornerstone of Successful Clinical Development

Complex therapeutic development requires deep integration across clinical, regulatory, statistical, and operational functions. Whether optimizing dose, navigating regulatory pathways, or accelerating timelines, early and sustained collaboration is...

READ MORE